title: Breast cancer subtype and distant recurrence after ipsilateral breast tumor recurrence.
abstract: BACKGROUND
  There is little information about the impact of breast cancer subtype on prognosis after ipsilateral breast tumor recurrence (IBTR).
  
  
  METHODS
  One hundred eighty-five patients were classified according to breast cancer subtype, as approximated by estrogen receptor, human epidermal growth factor receptor 2 (HER2), and Ki-67, of IBTR, and we evaluated whether breast cancer subtype was associated with distant recurrence after IBTR.
  
  
  RESULTS
  There was a significant difference in distant disease-free survival (DDFS) after IBTR according to breast cancer subtype defined by a cutoff of the Ki-67 index of 20 % (p = 0.0074, log-rank test). The 5-year DDFS rates for patients with luminal A, luminal B, triple-negative, and HER2 types were 86.3, 57.1, 56.6, and 65.9 %, respectively. In addition, breast cancer subtype was significantly associated with distant recurrence after IBTR on adjustment for various clinicopathologic factors (p = 0.0027, Cox proportional hazards model).
  
  
  CONCLUSIONS
  Our study suggests that breast cancer subtype based on immunohistochemical staining predicts the outcomes of patients with IBTR. Further analyses are needed (UMIN-CTR number UMIN000008136).
authors.affiliation: Department of Breast and Endocrine Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan. isitobi-ma@mc.pref.osaka.jp
authors.forename: Makoto
authors.initials: M
authors.lastname: Ishitobi
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Okumura
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Arima
authors.forename: Atsushi
authors.initials: A
authors.lastname: Yoshida
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Nakatsukasa
authors.forename: Takuji
authors.initials: T
authors.lastname: Iwase
authors.forename: Tadahiko
authors.initials: T
authors.lastname: Shien
authors.forename: Norikazu
authors.initials: N
authors.lastname: Masuda
authors.forename: Satoru
authors.initials: S
authors.lastname: Tanaka
authors.forename: Masahiko
authors.initials: M
authors.lastname: Tanabe
authors.forename: Takehiro
authors.initials: T
authors.lastname: Tanaka
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Komoike
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Taguchi
authors.forename: Reiki
authors.initials: R
authors.lastname: Nishimura
authors.forename: Hideo
authors.initials: H
authors.lastname: Inaji
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001808:Blood Vessels / Q000473:pathology; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology* / Q000628:therapy; D018270:Carcinoma, Ductal, Breast / Q000378:metabolism* / Q000556:secondary / Q000628:therapy; D018275:Carcinoma, Lobular / Q000378:metabolism* / Q000556:secondary / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D019394:Ki-67 Antigen / Q000378:metabolism; D042601:Lymphatic Vessels / Q000473:pathology; D015412:Mastectomy, Segmental; D008875:Middle Aged; D015999:Multivariate Analysis; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000378:metabolism* / Q000473:pathology* / Q000628:therapy; D016016:Proportional Hazards Models; D018714:Radiotherapy, Adjuvant; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism
chemical_list: D019394:Ki-67 Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; C508053:ERBB2 protein, human